RxDoctor Payments Data

Trisha Volmering, MD

Ophthalmology · Cincinnati, OHNPI 1992237408

Payments from drug & device makers

$7,227in general payments, 2019–2025

Across 101 payments — averaging $71.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotissue Holdings Inc.$3K
  • Carl Zeiss Meditec USA, Inc.$1K
  • AbbVie$551
  • Alcon$420
  • Johnson & Johnson Surgical Vision, Inc.$364
  • Harrow Eye, LLC$323
  • plus $1K from 13 others

What the payments were for

  • Travel & lodging$2,31632%
  • Food & beverage$3,58650%
  • Other$1,32518%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,227 in reported general payments places this provider in the 85th percentile of 640 ophthalmology providers in Ohio.

See all ophthalmology providers in Ohio

Medicare billing

Part B allowed, 2024
$204,720
Medicare patients
596
Services billed
1,453

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XdemvyLotilaner58$107,808
RestasisCyclosporine114$94,715
XiidraLifitegrast43$41,489
TyrvayaVarenicline Tartrate21$18,798
MieboPerfluorohexyloctane/Pf20$17,922
RhopressaNetarsudil Mesylate35$13,222
Cyclosporine21$9,581
LumiganBimatoprost13$9,068
VevyeCyclosporine11$8,082
RocklatanNetarsudil Mesylat/Latanoprost15$5,876
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat142$1,563
Latanoprost219$1,556
Fluorometholone18$1,316
Prednisolone Acetate36$1,273
ErythromycinErythromycin Base87$918

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Tarsus Pharmaceuticals, Inc.Xdemvy$309$107,80858 claims
AbbVieRestasis, Lumigan$551$103,783127 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo$15$59,41163 claims
Oyster Point Pharma, Inc.Tyrvaya$53$18,79821 claims
Harrow Eye, LLCVevye$323$8,08211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 640 ophthalmology providers in Ohio.

Other ophthalmology in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →